• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by REGENXBIO Inc.

    6/13/25 4:30:45 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RGNX alert in real time by email
    S-8 1 rgnx-20250613.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on June 13, 2025

     

    Registration No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    REGENXBIO Inc.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware

    47-1851754

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

     

     

    9804 Medical Center Drive

    Rockville, Maryland 20850

    (Address of Principal Executive Offices and Zip Code)

     

    REGENXBIO INC. 2025 Equity Incentive Plan

     

    (Full title of the plans)

    Mitchell Chan

    Chief Financial Officer

    REGENXBIO Inc.

    9804 Medical Center Drive

    Rockville, Maryland 20850

    (Name and address of agent for service)

    (240) 552-8181

    (Telephone number, including area code, of agent for service)

    Copies to:

     

    Kerry Shannon Burke

    Patrick J. Christmas

    Matthew C. Franker

    EVP, Chief Legal Officer

    Covington & Burling LLP

    REGENXBIO Inc.

    One CityCenter

    9804 Medical Center Drive

    850 Tenth Street, N.W.

    Rockville, Maryland 20850

    Washington, D.C. 20001

    (240) 552-8181

    (202) 662-6000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b‑2 of the Exchange Act.

     

    Large accelerated filer

    

    Accelerated filer

    

    Non-accelerated filer

    

    Smaller reporting company

    

    

    

    Emerging growth company

    

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. 

     

     

     


     

    PART I

    The information required by Item 1 and Item 2 of this Part I of Form S-8 is omitted from this Registration Statement on Form S-8 (this “Registration Statement”) in accordance with Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”), and the introductory note to Part I of Form S-8. REGENXBIO Inc. (the “Company”) will deliver the documents containing the information specified in Part I to the participants in the REGENXBIO Inc. 2025 Equity Incentive Plan as required by Rule 428(b)(1) under the Securities Act.

     

     

    PART II

    Information Required in the Registration Statement

     

    Item 3. Incorporation of Documents by Reference.

     

    We file annual, quarterly and current reports, proxy statements, and other information with the United States Securities and Exchange Commission (the “SEC”). Our filings with the SEC are available on the SEC’s website at www.sec.gov and on our website at www.regenxbio.com as soon as reasonably practicable after we file such material with, or furnish it to, the SEC. However, the information on our website is not incorporated by reference herein, and is not a part of this prospectus, any prospectus supplement or any of our other filings with the SEC.

     

    The following documents (File No. 001-37553) previously filed with the SEC are hereby incorporated by reference:

     

    •
    our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 13, 2025 (the “2024 Annual Report”);

     

    •
    our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 12, 2025;

     

    •
    our Current Reports on Form 8-K filed with the SEC on January 14, 2025 (Item 1.01 only), March 4, 2025 (Item 8.01 only), May 19, 2025 (Items 1.01 and 2.03 only) and June 3, 2025; and

     

    •
    the description of our common stock contained in Exhibit 4.2 to our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 13, 2025, including any amendments or reports filed for the purposes of updating this description.

     

    All reports and other documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, prior to the filing of a post-effective amendment which indicates that all securities registered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents, except as to specific sections of such statements as set forth therein.

     

    Unless expressly incorporated into this Registration Statement, a report furnished under Item 2.02 or Item 7.01 of Form 8-K (or any portion thereof so furnished) prior or subsequent to the date hereof shall not be incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

     


     

    Item 5. Interests of Named Experts and Counsel.

     

    The validity of the shares of common stock being registered under this Registration Statement has been passed upon for us by Covington & Burling LLP, Washington DC.

     

    Item 6. Indemnification of Directors and Officers.

     

    Section 102 of the Delaware General Corporation Law permits a corporation to eliminate the personal liability of its directors to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his or her duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Section 145 of the Delaware General Corporation Law authorizes a court to award, or a corporation’s board of directors to grant, indemnity to directors and officers under certain circumstances and subject to certain limitations. The terms of Section 145 of the Delaware General Corporation Law are sufficiently broad to permit indemnification under certain circumstances for liabilities, including reimbursement of expenses incurred, arising under the Securities Act.

     

    As permitted by the Delaware General Corporation Law, our restated certificate of incorporation and amended and restated bylaws contain provisions relating to the limitation of liability and indemnification of directors and officers. The restated certificate of incorporation provides that our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duty as a director, except for liability:

     

    •
    for any breach of the director’s duty of loyalty to us or our stockholders;

     

    •
    for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;

     

    •
    in respect of unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the Delaware General Corporation Law; or

     

    •
    for any transaction from which the director derives any improper personal benefit.

     

    Our restated certificate of incorporation also provides that if Delaware law is amended after the approval by our stockholders of the certificate of incorporation to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of our directors will be eliminated or limited to the fullest extent permitted by Delaware law.

     

    Our amended and restated bylaws provide that we will indemnify our directors and officers to the fullest extent permitted by Delaware law, as it now exists or may in the future be amended, against all expenses and liabilities reasonably incurred in connection with their service for or on our behalf. Our amended and restated bylaws provide that we shall advance the expenses incurred by a director or officer in advance of the final disposition of an action or proceeding, and permit us to secure insurance on behalf of any director, officer, employee, or other enterprise agent for any liability arising out of his or her action in that capacity, whether or not Delaware law would otherwise permit indemnification.

     

    We either have entered or intend to enter into indemnification agreements with each of our directors and executive officers and certain other key employees. The form of agreement provides that we will indemnify each of our directors, executive officers and such other key employees against any and all expenses incurred by that director, executive officer, or other key employee because of his or her status as one of our directors, executive officers, or other key employees, to the fullest extent permitted by Delaware law, our restated certificate of incorporation and our amended and restated bylaws. In addition, the form agreement provides that, to the fullest extent permitted by Delaware law, we will advance all expenses incurred by our directors, executive officers and other key employees in connection with a legal proceeding.

     

    We currently carry and intend to continue to carry liability insurance for our directors and officers.

     


     

     

    At present, there is no pending litigation or proceeding involving any of our directors, officers or employees in which indemnification will be required or permitted. We are not aware of any threatened litigation or proceeding that might result in a claim for such indemnification.

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     


     

    Item 8. Exhibits.

     

    Exhibit No.

    Description

    4.1*

    Restated Certificate of Incorporation (incorporated by reference from Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on June 7, 2021).

    4.2*

    Amended and Restated Bylaws (incorporated by reference from Exhibit 3.2 to the Company’s Current Report on Form 8-K, filed with the SEC on September 22, 2015).

    4.3*

    Specimen stock certificate evidencing the shares of Common Stock (incorporated by reference from Exhibit 4.1 to the Company’s Registration Statement on Form S-1, filed with the SEC on August 17, 2015).

    5.1

    Opinion and Consent of Covington & Burling LLP.

    23.1

    Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.

    23.2

    Consent of Covington & Burling LLP (contained in Exhibit 5.1).

    24.1

    Power of Attorney (contained on signature page hereto).

    99.1

    REGENXBIO Inc. 2025 Equity Incentive Plan.

    107

    Filing Fee Table.

     

    * Incorporated by reference

     

     


     

    Item 17. Undertakings

     

    The undersigned registrant hereby undertakes:

     

    (1)
    To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i)
    To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

     

    (ii)
    To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Filing Fee Table” attached as an exhibit to the effective Registration Statement; and

     

    (iii)
    To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;

     

    provided, however, that paragraphs (1)(i) and (1)(ii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in this Registration Statement.

     

    (2)
    That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3)
    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (4)
    That, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant’s annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (5)
    Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted against the registrant by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.

     


     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Rockville, State of Maryland, on this 13th day of June, 2025.

     

    REGENXBIO INC.

     

     

    By:

    /s/ Curran Simpson

     

    Curran Simpson

     

    President and Chief Executive Officer

     

    POWER OF ATTORNEY AND SIGNATURES

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Curran Simpson, Mitchell Chan and Patrick J. Christmas, and each of them, as his or her true and lawful attorneys-in-fact and agents with full power of substitution and resubstitution, for him or her in any and all capacities, to sign any and all amendments to this Registration Statement on Form S-8 (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the United States Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

    Title

    Date

     

    /s/ Curran Simpson

    Curran Simpson

     

     

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

     

    June 13, 2025

    /s/Mitchell Chan

    Mitchell Chan

     

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

    June 13, 2025

    /s/ Kenneth T. Mills

    Kenneth T. Mills

     

    Chairman of the Board of Directors

    June 13, 2025

    /s/ Jean Bennett

    Jean Bennett

     

    Director

    June 13, 2025

    /s/ Allan M. Fox

    Allan M. Fox

     

    Director

    June 13, 2025

    /s/ Alexandra Glucksmann

    Alexandra Glucksmann

     

    Director

    June 13, 2025

    /s/ A.N. “Jerry” Karabelas

    A.N. “Jerry” Karabelas

     

    Director

    June 13, 2025

    /s/ George Migausky

    George Migausky

     

    Director

    June 13, 2025

    /s/ David C. Stump

    David C. Stump

     

    Director

    June 13, 2025

    /s/ Daniel Tassé

    Daniel Tassé

     

    Director

    June 13, 2025

    /s/ Jennifer Zachary

    Jennifer Zachary

    Director

    June 13, 2025

     

     


    Get the next $RGNX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $RGNX

    DatePrice TargetRatingAnalyst
    2/11/2025$38.00 → $14.00Buy → Neutral
    Goldman
    2/7/2025$27.00Outperform
    Raymond James
    11/15/2024$22.00Overweight
    Morgan Stanley
    10/10/2024$18.00Outperform
    Raymond James
    6/7/2024$38.00Buy
    Goldman
    3/11/2024$36.00Buy
    H.C. Wainwright
    3/8/2024$20.00 → $35.00Sector Perform → Outperform
    RBC Capital Mkts
    3/6/2024$37.00Market Perform → Outperform
    Leerink Partners
    More analyst ratings

    $RGNX
    SEC Filings

    See more
    • SEC Form EFFECT filed by REGENXBIO Inc.

      EFFECT - REGENXBIO Inc. (0001590877) (Filer)

      6/26/25 12:15:15 AM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B3 filed by REGENXBIO Inc.

      424B3 - REGENXBIO Inc. (0001590877) (Filer)

      6/25/25 4:15:08 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-3 filed by REGENXBIO Inc.

      S-3 - REGENXBIO Inc. (0001590877) (Filer)

      6/13/25 5:19:17 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Simpson Curran covered exercise/tax liability with 4,701 shares, decreasing direct ownership by 2% to 252,331 units (SEC Form 4)

      4 - REGENXBIO Inc. (0001590877) (Issuer)

      7/3/25 6:53:52 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Fox Allan M. was granted 7,768 shares, increasing direct ownership by 69% to 19,054 units (SEC Form 4)

      4 - REGENXBIO Inc. (0001590877) (Issuer)

      6/3/25 4:37:11 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Zachary Jennifer was granted 7,768 shares, increasing direct ownership by 54% to 22,064 units (SEC Form 4)

      4 - REGENXBIO Inc. (0001590877) (Issuer)

      6/3/25 4:33:55 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • REGENXBIO downgraded by Goldman with a new price target

      Goldman downgraded REGENXBIO from Buy to Neutral and set a new price target of $14.00 from $38.00 previously

      2/11/25 7:12:20 AM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Raymond James resumed coverage on REGENXBIO with a new price target

      Raymond James resumed coverage of REGENXBIO with a rating of Outperform and set a new price target of $27.00

      2/7/25 8:29:59 AM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Morgan Stanley resumed coverage on REGENXBIO with a new price target

      Morgan Stanley resumed coverage of REGENXBIO with a rating of Overweight and set a new price target of $22.00

      11/15/24 8:17:57 AM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGNX
    Leadership Updates

    Live Leadership Updates

    See more
    • Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, Dec. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from t

      12/6/24 6:29:00 PM ET
      $AMTM
      $APO
      $CMA
      $CRI
      Investment Managers
      Finance
      Major Banks
      Apparel
    • REGENXBIO Appoints Mitchell Chan as Chief Financial Officer

      Life sciences veteran Mitchell Chan joins the company ahead of multiple catalysts across late-stage gene therapy programsVit Vasista steps down following more than 15 years at the CompanyROCKVILLE, Md., Sept. 17, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that Mitchell Chan has been appointed as Executive Vice President and Chief Financial Officer, effective today. A veteran finance executive and operating partner in the biotechnology industry, Mr. Chan has held key roles in raising capital, business development transactions and operations for nearly 20 years.  "We are excited to welcome Mitchell at this exciting time for REGENXBIO," said Curran Simpson, President and

      9/17/24 7:05:00 AM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • REGENXBIO Announces Leadership Transition

      Curran Simpson, Chief Operating Officer, Appointed as President and CEOCo-Founder Kenneth T. Mills to Step Down as President and CEO; Named Chairman of the Board ROCKVILLE, Md., June 12, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that Curran Simpson, Chief Operating Officer, has been appointed as President, Chief Executive Officer and a member of the Board of Directors, effective July 1, 2024. Co-Founder Kenneth T. Mills will step down as President and Chief Executive Officer following 15 years of leadership at the Company, and he is taking on an expanded role on the Board as Chairman. In connection with these changes, Board member Daniel Tassé has been appointed as RE

      6/12/24 7:05:00 AM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

      SC 13G/A - REGENXBIO Inc. (0001590877) (Subject)

      11/14/24 9:00:57 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

      SC 13G/A - REGENXBIO Inc. (0001590877) (Subject)

      11/12/24 4:47:45 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

      SC 13G/A - REGENXBIO Inc. (0001590877) (Subject)

      11/4/24 1:49:56 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGNX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy

      Construct including CT domain demonstrated higher levels of microdystrophin protein, increased muscle force, and improved resistance to damage in mice lacking dystrophin REGENXBIO's next-generation investigational gene therapy, RGX-202, is the only microdystrophin construct that includes the CT domain Findings support the positive functional data seen in Phase I/II AFFINITY DUCHENNE® trial of RGX-202ROCKVILLE, Md., July 10, 2025 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced the publication of preclinical results comparing a microdystrophin gene therapy construct that included the C-terminal (CT) domain to a microdystrophin construct without the CT domain. The results, which we

      7/10/25 11:54:00 AM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

      RGX-202 demonstrating consistent evidence of positively changing disease trajectory for Duchenne All dose level 2 participants exceeded external natural history controls on all functional measuresBiomarker data demonstrate consistent, robust microdystrophin expression and transduction levels across all treated ages One new participant aged 2 years at dosing had expression level at 118.6% compared to controlFavorable safety profile continues with no serious adverse events or adverse events of special interest observed Webcast to be held at 8:00 a.m. todayROCKVILLE, Md., June 5, 2025 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced new positive interim data from the Phase I/II AFFI

      6/5/25 7:05:00 AM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202

      Event will feature Aravindhan Veerapandiyan, M.D., principal investigator of the AFFINITY DUCHENNE® trialROCKVILLE, Md., June 2, 2025 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a webcast to discuss new interim functional data from the Phase I/II AFFINITY DUCHENNE® trial of RGX-202, the company's next-generation investigational gene therapy for the treatment of Duchenne muscular dystrophy. The webcast will feature AFFINITY DUCHENNE principal investigator Aravindhan Veerapandiyan, M.D., Arkansas Children's Hospital. Webcast detailsTitle: AFFINITY DUCHENNE® Trial of RGX-202: Phase I/II Interim Functional DataDate/Time: Thursday, June 5, 2025, at 8:00 a.m. EDT

      6/2/25 7:05:00 AM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGNX
    Financials

    Live finance-specific insights

    See more
    • REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights

      RGX-202 in Duchenne muscular dystrophy on track for BLA submission mid-2026Pivotal trial more than half enrolled, with completion expected in 2025 Additional Phase I/II functional data expected 1H 2025 Initiating commercial supply manufacturing in Q3 2025FDA acceptance of Biologics License Application (BLA) for clemidsogene lanparvovec (RGX-121, partnered with Nippon Shinyaku) expected in May 2025 Pivotal data evaluating the safety and efficacy of the subretinal delivery of surabgene lomparvovec (ABBV-RGX-314, partnered with AbbVie) in patients with wet age-related macular degeneration are expected in 2026 and planning of diabetic retinopathy pivotal study continuesConference call today at 4

      5/12/25 4:05:00 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights

      ROCKVILLE, Md., April 30, 2025 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Monday, May 12, at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2025, and recent operational highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time. ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mi

      4/30/25 4:05:00 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

      ROCKVILLE, Md., Feb. 26, 2025 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Thursday, March 13, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2024, and recent operational highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time. ABOUT REGENXBIO Inc.REGENXBIO is a leading

      2/26/25 4:05:00 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care